Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
JPY 23240.00
JPY 18260.00
JPY 44820.00
JPY 61420.00
JPY 94620.00

カスタマーフィードバック(2)

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MoHOSpVv[3Srb36gRZN{[Xl? MnL3NVAh|ryP M4LuVVYhcA>? MWLpcoNz\WG|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJI93\XKneIDy[ZN{\WRiS1zIUFMh[XRiU{SzNy=> M4nDd|I3PDN3NEm4
Mo-DCs NX;OeJdETnWwY4Tpc44hSXO|YYm= MWC1NEDPxE1? NWHOcJh{OjUkgJno MX3wdo9ud3SnczDJUE0zOyCycn;keYN1cW:wIHnuJJRp\SC|dYDldo5ifGGwdDDv[kB7gW2xc3HuJJN1cW23bHH0[YQhVW9vRFPzxsA> NUPEVVlEOjZ2MUK5OFg>
RBMECs  MWTGeY5kfGmxbjDBd5NigQ>? M{HzfVXDqM7:TR?= NVj5ZZpJOcLiaB?= NGXCbXRjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? M4j3NlI3OzV6MEO5
INA-6 NX;SSZBqS2WubDDWbYFjcWyrdImgRZN{[Xl? NHrtcpoxNTFyMDFOwG0> M{Pic|cz6oDLaB?= M13veolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M1n0UlI3OzB4NkK0
OPM-2 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGTsbFYxNTFyMDFOwG0> M1m4Tlcz6oDLaB?= NXHwdG95cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NILFWoYzPjNyNk[yOC=>
U266 M3XFXWNmdGxiVnnhZoltcXS7IFHzd4F6 NFrFWG4xNTFyMDFOwG0> MWe3NwKBkWh? NUX5VYFqcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MVuyOlMxPjZ{NB?=
H929 M2i5cGNmdGxiVnnhZoltcXS7IFHzd4F6 M3jSVFAuOTByIN88US=> NI\3U204OuLCiXi= NXnUe21KcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> M3LpWVI3OzB4NkK0
RPMI 8226 Mnv0R4VtdCCYaXHibYxqfHliQYPzZZk> NFr4OYwxNTFyMDFOwG0> NV25bmd4PzMkgJno NVPKfWVLcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NHfpTmYzPjNyNk[yOC=>
MDCK  M4DMdWZ2dmO2aX;uJGF{e2G7 NWX5O5ZlOTBiwsXN MX:yOEBp MWrEUXNQ NITKZ5N2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB? M1jr[VI3OjB{M{Wy
MDCK  MWLGeY5kfGmxbjDBd5NigQ>? MVSxNEDDvU1? M33scFI1KGh? M2DoUmROW09? M160[olvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? M1ewdVI3OjB{M{Wy
Spinal cords  M1rxe2Z2dmO2aX;uJGF{e2G7 M3TaVFHDqM7:TR?= M3\vbFMxKG2rbh?= MlSzd5RqdXWuYYTld{BkSU2SIHzleoVtew>? NFfMPGkzPjF{NkmyOi=>
BeWo  Mo\USpVv[3Srb36gRZN{[Xl? M{W2TVI26oDLzszN MUmyOE81QC95MjDo MYPs[YFleyC2bzDhckBqdmO{ZXHz[UBqdiC2aHWg[ZhxemW|c3nvckBw\iCxdHjldkBnfXOrb36gcYFzc2W{cx?= MX6yOlA2OzV2OR?=
bovine oocytes MX;GeY5kfGmxbjDBd5NigQ>? NHSxVXQyODEEoN88US=> M3XZbFEzyqCq MWTpcohq[mm2czD0bIUh\W[oZXP0JI9nKE6SUFGgZY5lN2:{IF7QVGMhfG9ic4TpcZVt[XSnIILld5VueHSrb36gc4YhdWWrb4Ppdy=> M4fvb|I3ODVzNkGx
Caco-2  NXz5XFZyTnWwY4Tpc44hSXO|YYm= M1e0UlAvOS9zL{GwJO69VQ>? MUWyNOKhdWmw Mmm5bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiY1HNVEBt\X[nbIO= Ml6wNlYxPDlzMEK=
Caco-2  NWTtbFl2TnWwY4Tpc44hSXO|YYm= NW\5[ZZNOC5zL{GvNVAh|ryP MYeyOEBp NWTjR49ocW6lcnXhd4V{KE2UUEKgdJJwfGWrbjDs[ZZmdA>? M4HxUVI3ODR7MUCy
AML-12  MV7GeY5kfGmxbjDBd5NigQ>? MXWyNEDPxE1? NYPoRYJ[OyCq NGrwTGN2eHKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIHzleoVteyCjdDDUbJIuPDFzIHHu[EBU\XJvNEmz NF3pUlgzPjB2OEm4OS=>
AML-12  MXjGeY5kfGmxbjDBd5NigQ>? MUGyNEDPxE1? M{jvbVEuQCCq M{S1ZYlv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> NX7FS4xyOjZyNEi5PFU>
AML-12  MkHYSpVv[3Srb36gRZN{[Xl? MmLrNlAh|ryP M3LjSVMhcA>? MkHneZAuemWpdXzheIV{yqCSZ3OxZUzDqFCncHPrMEBidmUEoFe2dIPDqG2UTlGgcIV3\Wy| M1LQclI3ODR6OUi1
AML-12  MW\GeY5kfGmxbjDBd5NigQ>? MViyNEDPxE1? NIrTboo{KGh? NFi2VYxqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCxZjDDVnREOsLi Mm\NNlYxPDh7OEW=
RBMECs MkXaSpVv[3Srb36gRZN{[Xl? NIrGbVc2yqEQvF2= NETaT3kyKGh? M2TUc4lvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh NGfsRpUzPjB2NE[2Ny=>
EndoC-βH1 M{THRWZ2dmO2aX;uJGF{e2G7 MnrPOeKh|ryP MlXsNUBp M2PuT5BwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> MoPRNlYxOjh3NkK=
EndoC-βH1 MmX0SpVv[3Srb36gRZN{[Xl? M13iZVXDqM7:TR?= M37NRVEhcA>? NGDpW5Bt\WGmczD0c{BiKHO2cn;u[{BkSU2SIHnuZ5Jm[XOn Ml;pNlYxOjh3NkK=
SH-SY5Y NHXkUXpHfW6ldHnvckBCe3OjeR?= NELqfFE{OCEQvF2= MnLRN|AhdWmw Mn7DSG1UVw>? M13uWZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> M1jxRVI3ODJ3MUO3
PC-3 NX\EV4h6TnWwY4Tpc44hSXO|YYm= NYjVSINKPDBiwsXN MkPLNkBp NELXO|dFVVOR NUDyV|ZZdGWjZIOgeI8hWFB{QTDhZ5RqfmG2aX;u MlX1NlYxOjN6M{[=
PC-3 MmLkR4VtdCCYaXHibYxqfHliQYPzZZk> M2XWclQxKML3TR?= NYH4Zo5DOjRxNEivO|IhcA>? Mn3LSG1UVw>? Mn3V[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? M{\pd|I3ODJ|OEO2
SCG M17kXGZ2dmO2aX;uJGF{e2G7 MoTKNlAh|ryPwrC= NHuyUItFVVOR NEjYVoRz\X[ncoPpZox6KHO3cIDy[ZN{\XNiSVvWJJdqfGhiYTDJR|UxKG:oIEK0MlQh|ryP MXiyOVk3OjF|Mh?=
HEK-293 M{HKWmZ2dmO2aX;uJGF{e2G7 NHjKW28{PSEQvF5CpC=> NGPCPI1FVVOR MVrpcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 NIXqc48zPTl4MkGzNi=>
SCG NXKxbHVETnWwY4Tpc44hSXO|YYm= NYHMTHl5OTByIN88UeKh NV3HeHoxTE2VTx?= NU\3enlsemWmdXPld{B1cGViZYjjbZRi[mmuaYT5JI9nKFOFRzDu[ZVzd26| NY\ofYJqOjV7NkKxN|I>
PCCL3 NHL6OFdHfW6ldHnvckBCe3OjeR?= NYCzUZJyOTBiwsXN M3;HVVI1KGh? M3j5ZYVvcGGwY3XzJGR2V3h{IIDyc41wfGW{IITyZY5{[3KrcITpc44h[WO2aY\peJnDqOLCix?= M3L1S|I2QTZyOUW2
3T3-L1 preadipocytes MkPQSpVv[3Srb36gRZN{[Xl? Mn[5NVAh|ryPwrC= MorONVIhcA>? M1PH[Ylv\HWlZYOgR3JGSiCyaH;zdIhwenmuYYTpc44h[W6mIFOvSWJR|rJiZYjwdoV{e2mxbh?= NG\reFEzPTl{OEC1PC=>
H295R  MlH5SpVv[3Srb36gRZN{[Xl? NXjOeWZtOTEEoN88US=> MXi0POKhcA>? MWrpcoNz\WG|ZYOgd5Rmem:rZDDt[ZRi[m:uaYTld{BqdiC2aHWgZY5lem:pZX6sJI1qdmW{YXzvMUBidmRiZ3z1Z49kd3K2aXPvbYQheGG2aIfhfZM> NWL0XoZSOjV6Nkm1OVY>
PBMC MnTOSpVv[3Srb36gRZN{[Xl? M2XqPVUxyqEQvF2= NHLZ[GEzPMLiaNMg NY\Gepo4cW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= M3PxUFI2QDZ4MEe5
GLUTag  Mo\qSpVv[3Srb36gRZN{[Xl? Mly3NVDjiIoEtV2= MUWwM|IwPCCq MlHWd5RqdXWuYYTld{BIVFBvMTDz[YNz\XSrb36gZ491emWjdHXkJJdqfGhiSVLNXC=> M2j6U|I2QDN{NkOx
GLUTag  MnXrSpVv[3Srb36gRZN{[Xl? MnfCNVDjiIoEtV2= NFTrWo41KGh? MUjpcoNz\WG|ZYOgeIhmKHCFUlXCJIxmfmWuczD3bZRpKHSqZTDJRm1Z M3LXbVI2QDN{NkOx
BAECs MlTkSpVv[3Srb36gRZN{[Xl? NVHReJVJOjVizszN NFPUTnczPCCq NXfNXWRp\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> NGDvTmYzPTd7OEiyOi=>
PC12 MojrSpVv[3Srb36gRZN{[Xl? M2HkSVI2yqEQvF2= NV;SOmhwPDhiaB?= NUHYZZp2[WO2aY\heIV{KGODTWC= NFS2[2YzPTd4OUOwOS=>
GH3 MWPGeY5kfGmxbjDBd5NigQ>? MX[xxsDPxE1? M3fLO|YucA>? MUnheJRmdnWjdHXzJJRp\SClb4Ly[YxifGmxbjDi[ZR4\WWwIGDSUEBidmRiQn3hcFEh\XiycnXzd4lwdg>? M3LVXlI2PzJ5MEG4
GH3 MUTGeY5kfGmxbjDBd5NigQ>? M4DGSFHDqM7:TR?= MXO2MYg> M3LYUIlv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u NUP2SnJJOjV5MkewNVg>
BeWo NUHadIsxTnWwY4Tpc44hSXO|YYm= NE[zenUyOOLCit88UeKh MW[3NkBp NHyxbndFVVOR NUnr[29mdWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NFfZRoYzPTdzM{SyOS=>
oocytes Mnn5SpVv[3Srb36gRZN{[Xl? M2HtOFUh|ryP M1nwNFI1KGh? NEW1T2pifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= M2fzNFI2PzB5OEW0
SC M4D4VmZ2dmO2aX;uJGF{e2G7 MoW1NE42KM7:TR?= MkTHNlQhcA>? NYLx[lh3dWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= MlvQNlU4ODV6N{S=
SC MnXvSpVv[3Srb36gRZN{[Xl? M3jBTVAvPSEQvF2= NUnme2p[PzJiaB?= MWHpcoNz\WG|ZYOgZo91cCCNcn;4MVIxKGGwZDDPNUBmgHC{ZYPzbY9vKGmwIHH4c44uemWuYYTl[EBUS3NiYoX0JI9vdHliS4LvfE0zOMLi NVGxdnpKOjV5MEW4O|Q>
UACC-647  MnS1SpVv[3Srb36gRZN{[Xl? M3vjSWROW09? MoPXcIVi\HNidH:gZUBzcXOnIHnuJINCVVBibHX2[Yx{KCiHQ{WwxsA:yqB{MD6zPeKh|ryPKR?= MofuNlU4ODNyMkW=
UACC-647  NUHETJNHTnWwY4Tpc44hSXO|YYm= NFW2Z5oyOMLizszN NEjld3IyPSCvaX6= MnXjSG1UVw>? M2\ve4lvcGmkaYTzJGVTUyCyaH;zdIhwenmuYYTpc44> MXeyOVcxOzB{NR?=
UACC-647  MoTFSpVv[3Srb36gRZN{[Xl? NVvubphvOTEEoN88US=> MX:xOUBucW5? M17YUGROW09? NXn6bnZNcW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li NILufY8zPTdyM{CyOS=>
SH-SY5Y  NXvG[IVyTnWwY4Tpc44hSXO|YYm= MoTGNVDDqM7:TR?= NIfjV|AyyqCqwrC= MV\pcoNz\WG|ZYOgUHVEKGGldHn2bZR6 NYf6d|g6OjV3OUe0N|M>
SH-SY5Y  M{G4NmZ2dmO2aX;uJGF{e2G7 M2rkW|ExyqEQvF2= NGOxbnYyyqCqwrC= Moj4bY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= MU[yOVU6PzR|Mx?=
hADSCs MoP4SpVv[3Srb36gRZN{[Xl? MVi15qCKyrWP M1fJ[VMxKG2rbh?= NUjGb3hEcW6lcnXhd4V{KGODTWCgcIV3\Wy| NX3xPIl[OjV3OUG5NFg>
HEK293  NFHrSWpHfW6ldHnvckBCe3OjeR?= MoHmOgKBkcL3TR?= MVizNEBucW5? M2G3OIlv[3KnYYPld{BkSU2SIHzleoVtew>? Ml7PNlU2QTF7MEi=
3T3-L1 MojHSpVv[3Srb36gRZN{[Xl? NFnnbXgzNjVxNTFOwG0> NWXvbpZnOjRiaNMg M1uxXJNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? NF;GWpUzPTV7MEW5Oy=>
OCI-Ly1  MnjNSpVv[3Srb36gRZN{[Xl? NWPtWo9KPDEEoN88US=> Mon4NeKhcMLi NGPRR3lFVVOR NX7qc5JlcW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> NXv3U5lPOjV3N{[yNlA>
OCI-Ly18  NGjTb3NHfW6ldHnvckBCe3OjeR?= NI\sV4M1OMLizszN MVOxxsBpyqB? NWnXcJhlTE2VTx?= NGXKZmZqdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> NEDQSFAzPTV5NkKyNC=>
BeWo MnjFSpVv[3Srb36gRZN{[Xl? NVzRSnN6OjEEoNM1US=> NWX2Om1RPDkEoHi= MV7EUXNQ NVrKWYducW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> MYeyOVU3Pjd2MB?=
BeWo NX7je3hRTnWwY4Tpc44hSXO|YYm= Mn:5NlDDqML3TR?= M4q1[VQ5yqCq NHv1TpBFVVOR M2WydIlv[3KnYYPld{B1cGViYXTo[ZNqd25ib3[gWGhRNTFibX;uc4N6fGW| M1faR|I2PTZ4N{Sw
LNCaP  MojBSpVv[3Srb36gRZN{[Xl? M3jhO|ExyqEQvF2= M3PCUVEzKGkEoB?= NEXTcmdFVVOR MWLpcoR2[2W|IHGg[JJidWG2aXOgbY5kemWjc3Wgc4YhS1KHQkGgZYN1cX[rdIm= MoHxNlU2PDhyOUm=
ThGCs  M4\Uc2Z2dmO2aX;uJGF{e2G7 NEfOT4IyOOLCit88US=> NHjibYs16oDMaB?= MXPheYdu\W62czDITWYySSCuZY\lcJMhfGijdDD3[ZJmKHO2aX31cIF1\WRiYomgR49EdDJ? MmjPNlU1OzNyMke=
ThGCs  MkOzSpVv[3Srb36gRZN{[Xl? MUexNQKBks7:TR?= M4\ZPFTjiIqq MlznbY5kemWjc3XzJGNwS2x{LXnu[JVk\WRiRVTONuKh\2WwZTDlfJBz\XO|aX;u MlyxNlU1OzNyMke=
ThGCs  NVy1Vm1STnWwY4Tpc44hSXO|YYm= MXWxNQKBks7:TR?= Mmf3N{Bp NHfnSmlqdmirYnn0d{B1cGViZX\m[YN1KG:oIFiyU|Ihd25iRVTONkBuWk6D NXfzXHk{OjV2M{OwNlc>
RBMECs NX7LTpppTnWwY4Tpc44hSXO|YYm= M1HOcVAvODVxMD61M|Uh|ryP NYLN[2JNOC5{NTDo MVrpcoNz\WG|ZYOgZ2FOWCClb37j[Y51emG2aX;u MkCxNlU1OTZ4NUG=
RBMECs MnH6SpVv[3Srb36gRZN{[Xl? NHXqcHc2yqEQvF2= MUOxJIg> NFzHVopjdG:la4OgeIhmKGGldHn2ZZRqd25ib3[gVohwSS:UT1PLJIlv\HWlZXSgZpkhTU2DUD3JTS=> NUXYfIxGOjV2MU[2OVE>
RBMECs MUnGeY5kfGmxbjDBd5NigQ>? NHLO[XQ2yqEQvF2= MmDPNUBp M4O2fJBz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? MWiyOVQyPjZ3MR?=
RBMECs Ml:ySpVv[3Srb36gRZN{[Xl? MlH1OeKh|ryP NWLve5lZOSCq MnLydJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIFjSVEBndHW6IHHjdo9{eyC2aHWgRnRDKGmwZIXj[YQh[nliIFXNRXAuUUl? MUiyOVQyPjZ3MR?=
RBMECs M4\FU2Z2dmO2aX;uJGF{e2G7 NX;ZbmNsPcLizszN NYG1TpUyOSCq M1vMSolvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? MmDqNlU1OTZ4NUG=
RBMECs MXTGeY5kfGmxbjDBd5NigQ>? M1rBV|XDqM7:TR?= M1njVVEhcA>? NIj1doRz\X[ncoPld{B1cGViY3jhcodmeyCrbjDaU{0yKGSrc4TybYJ2fGmxbjDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboS= MW[yOVQyPjZ3MR?=
RBMECs NEfvVHdHfW6ldHnvckBCe3OjeR?= M37qVVXDqM7:TR?= MlPQNUBp NUfzOZg5[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? NVnyVWFUOjV2MU[2OVE>
RBMECs NVLBVFVwTnWwY4Tpc44hSXO|YYm= NX7XdlRGPcLizszN M3zqOVEhcA>? NYPlU2l4[myxY3vzJJRp\SCjY4TpckBkgXSxc3vlcIV1d25icnXhdpJidmenbXXueEB{\WWwIIfpeIghTU2DUD3JTUB1emWjdH3lcpTDqA>? MYiyOVQyPjZ3MR?=
Primary bovine chondrocytes M3X5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jDeFXPxE1? MnvoOFghcA>? MnLXdoV3\XK|ZYOgeIhmKGmwaHnibZRwenliZX\m[YN1KG:oIHPlcIVkd3irYjDvckBxem:uaX\ldoF1cW:wIHnuJIdzd3e2aDDwcIF1\SClaH;u[JJw[3m2ZYO= MXiyOVQxPjBzNh?=
EM1  NUn5SJRmTnWwY4Tpc44hSXO|YYm= M4PXc|E26oDMzszN NIjs[Zc1QCCq NVy0UIlSemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? NEfXfIozPTN5OE[2NS=>
BeWo  NIL5S|ZHfW6ldHnvckBCe3OjeR?= MnKzNlDDqML3TR?= NFnqd5U1QMLiaNMg NVfGU5JwTE2VT9Mg M3PwN4lv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? MWmyOVM3OjJ4MB?=
BeWo  MUXGeY5kfGmxbjDBd5NigQ>? NHrZXYozOMLiwsXN MV20POKhcMLi NEPGXmVFVVORwrC= M3zDS4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJHROTU2IMU[= NH75bFkzPTN4MkK2NC=>
BeWo  MYrGeY5kfGmxbjDBd5NigQ>? NUTKT|Y4OjEEoNM1US=> NXzlfFhRPDkEoHlCpC=> MkfBSG1UV8Li M{HoWYRwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGdEVS1z MXeyOVM3OjJ4MB?=
granulosa cells MUTGeY5kfGmxbjDBd5NigQ>? NEjKW5UyOCEQvF2= M3zGNVEzNzJ2IHi= NITBUVRqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> M2\UelI2OzN7MUC1
granulosa cells NXTlXWZvTnWwY4Tpc44hSXO|YYm= MoPyNVAh|ryP NELKV|MyOi9{NDDo MYHpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC{ZYDvdpRmeiCjY4Tpeol1gSCob4KgeIhmKGyxbnfld5Qh\nKjZ33lcpQhMOLKkki1OE8sOTiUR2OyMmxWSyl? NUPH[lBSOjV|M{mxNFU>
granulosa cells NEXSeHNHfW6ldHnvckBCe3OjeR?= NYjE[WVnOTBizszN M{jFSVI1KGh? NEnPV5RqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 MljxNlU{OzlzMEW=
granulosa cells M3TYRmZ2dmO2aX;uJGF{e2G7 M1jlRVExKM7:TR?= MWiyOEBp MkD0bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUlfTNkBxem:vb4TldkBi[3Srdnn0fS=> MYeyOVM{QTFyNR?=
SK-N-AS  NGP5fGdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{nX[lExKM7:TdMg MXuyOE81QCCq M13SUoVvcGGwY3XzJJRqdWVvZHXw[Y5l\W62bImgZ4VtdHWuYYKgeoli[mmuaYT5xsA> NILhN3UzPTJ4NkC2Ny=>
SK-N-AS  M136XmZ2dmO2aX;uJGF{e2G7 NGO5ZoQyOCEQvF5CpC=> M1O1[|I1KGh? MnL0bY5kemWjc3XzJJRp\SClQV3QJIxmfmWuc9Mg MUGyOVI3PjB4Mx?=
SK-N-AS  M3LzN2Z2dmO2aX;uJGF{e2G7 MoPlNVAh|ryPwrC= MWSyOEBp M1jQ[Ylv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> MoDxNlUzPjZyNkO=
SK-N-AS  M{K5ZmZ2dmO2aX;uJGF{e2G7 M2XPW|ExKM7:TdMg NFLwWXk{OCCvaX6= NFH4e3FqdmS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kDPui2lYYTlcolvKCi|ZYK2O|UqNCCyLVfTT|PPuiBqc3XyPUkh[W6mIHPvcoNwdWm2YX70JIhq\2incjDs[ZZmdHNib3[gZYN1cX[nLDD1cpBpd3OyaH;yfYxifGWmLDFOtk1k[XSnbnnu MWeyOVI3PjB4Mx?=
SK-N-AS  Ml7uSpVv[3Srb36gRZN{[Xl? NVnkWm1GOTBizszNxsA> NYrtSHN5OTBxM{CvOlAhdWmw Ml\JbY5kemWjc3XzJIxmfmWuczDv[kBxNc7{LXPheIVvcW5iKIPldlY4PSliYX7kJIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIICt{tIu[2G2ZX7pckApe2W{Nke1LUBqdiBqcHXybUlvfWOuZXHyJJJm\2mxboO= MY[yOVI3PjB4Mx?=
SK-N-SH MnfyR4VtdCCYaXHibYxqfHliQYPzZZk> MWmxNEDPxE4EoB?= NXPQO3JGPDhiaB?= NYDlUXI5\W6qYX7j[ZMhW0tvTj3TTEBv\XW{b3LsZZN1d22jIHPlcIwhfmmjYnnsbZR6 MWGyOVI3PjB4Mx?=
HEK‐CFTR NFHJSJNHfW6ldHnvckBCe3OjeR?= NYTmRlNxOuLCk{WwxsDPxE1? M{jKd|AuOTJibXnu NYnCNVk3TE2VT9Mg M2LKcolv\HWlZYOgZUBld3On4pEQ[IVx\W6mZX70JIlw\GmmZTDl[oZtfXkEoB?= NGCx[nozPTJ4M{KwOy=>
L6 NWPNc2dyTnWwY4Tpc44hSXO|YYm= Mon5OFAhyrWP M3viT|I1KGh? NYjVeFJWcW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v NEnvd5ozPTJ2N{W1NC=>
MIN6  NYezdlA1TnWwY4Tpc44hSXO|YYm= NH3PbZoyOCEQvF5CpC=> MUCzJIg> NH3RWZVqdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v NHzlWZgzPTJ2MUGyOC=>
ventricular cardiomyocytes  NXe4SmZFTnWwY4Tpc44hSXO|YYm= NWrNc3VsOC5yMT2xNEDPxE1? MYDpcoNz\WG|ZYOgJINCVVBiYXPjeY12dGG2aX;u M2PFRVI2OjB|MUGz
ventricular cardiomyocytes  MkSwSpVv[3Srb36gRZN{[Xl? Mkj5NE4xOS1zMDFOwG0> MWDleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=> NYHa[oNQOjV{MEOxNVM>
BeWo  MYrGeY5kfGmxbjDBd5NigQ>? MVqyNEDDvU1? NILEbnM1QCCq NGS4XJBFVVORwrC= MXzpcoR2[2W|IHPlcIwh\nW|aX;u Ml;6NlUyQDR2N{e=
THP-1  NWrGbW1ITnWwY4Tpc44hSXO|YYm= NVvrVmpkOS9zMDFOwG0> NFLOfowzyqCq MXvEUXNQyqB? MlK2d5VxeHKnc4Pld{BOS1BvMTDwdo9lfWO2aX;uxsA> NUT5ZYUzOjVzNUS4PFI>
Huh-7 M3[3bWZ2dmO2aX;uJGF{e2G7 MUmwMVIxKM7:TR?= NHPhXWIzKGkEoB?= Mny5doV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| NEPo[5EzPTFyOUizOC=>
C6 NF\0UpZHfW6ldHnvckBCe3OjeR?= M4rYd|ExKM7:TdMg NYD5SWNuOjBibXnu NGKwdlBqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> NUfyPGJtOjVyNkm0NVc>
SW480 NEmzUGpHfW6ldHnvckBCe3OjeR?= M3jnRVQxyqEQvF2= NFO2VFU1QMLiaB?= Mof5SG1UVw>? M{K0NoFkfGm4YYTld{BRWDKD Mo\pNlQ6QTd2NUG=
HT-29  M{fHXmZ2dmO2aX;uJGF{e2G7 NILy[4Y1OMLizszN NIGxfnY1QMLiaB?= NHvV[VFFVVOR M4\NPYFkfGm4YYTld{BRWDKD NHPBPYIzPDl7N{S1NS=>
SW480 NGLuTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexOFDDqM7:TR?= MVKwMVczKGh? MmDZSG1UVw>? NUPRV5hWcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NVG2VGtMOjR7OUe0OVE>
HT-29  MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV60NOKh|ryP Mlr6NE04OiCq MULEUXNQ MmfmbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> Mlu2NlQ6QTd2NUG=
SW480 NX;pXWVMTnWwY4Tpc44hSXO|YYm= MXm0NOKh|ryP NXH1WFBvPyCm M{jKU2ROW09? M2TBeZJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NGrvbpAzPDl7N{S1NS=>
HT-29  M4rJdGZ2dmO2aX;uJGF{e2G7 NXrlU2dSPDEEoN88US=> MVu3JIQ> MoP1SG1UVw>? M2f5dJJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NF;JTm8zPDl7N{S1NS=>
SW480 MojmRZBweHSxc3nzJGF{e2G7 MojlOFDDqM7:TR?= M1LsUlQ5yqCq NF3zbpBFVVOR NYPtfoVpcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 M1PsOlI1QTl5NEWx
HT-29  MnPhRZBweHSxc3nzJGF{e2G7 Mn3HOFDDqM7:TR?= M{HJeFQ5yqCq NHTZ[ZlFVVOR NHW5dG1qdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> M{XIPFI1QTl5NEWx
SW480 M1HoT2Fxd3C2b4Ppd{BCe3OjeR?= NX;OTpo5PDEEoN88US=> MWi0POKhcA>? MXTEUXNQ MljybY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= MVGyOFk6PzR3MR?=
HT-29  M4PlV2Fxd3C2b4Ppd{BCe3OjeR?= M4LqOlQxyqEQvF2= MnLnOFjDqGh? NFfoOY1FVVOR NEjONppqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz Ml6yNlQ6QTd2NUG=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
in solvent
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID